Biotech | January 18, 2022
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
This surpasses the number of approvals supported in 2020
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
The transaction is expected to close in the first quarter of 2022
Hitz shall assume new role from January 17th, 2022
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
Subscribe To Our Newsletter & Stay Updated
